---
layout: default
title: Activated Charcoal Aethusa Cynapium Apomorphine Hy
parent: 僅模型預測 (L5)
nav_order: 159
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Aethusa Cynapium Apomorphine Hy
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Homeopathic Preparation: Insufficient Evidence for Repurposing Evaluation

## One-Sentence Summary

This submission contains a 12-ingredient combination product — including Activated Charcoal, Apomorphine Hydrochloride, Ipecac, Colchicum Autumnale, and several homeopathic botanicals — whose precise clinical indication is not established in the provided data.
The TxGNN model returned **no predicted new indications** for this combination, likely because no DrugBank ID could be mapped to this multi-component entry.
Without a TxGNN prediction score, clinical trial linkage, or literature support, a formal repurposing evaluation cannot be completed at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no registered license found) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | — |
| Evidence Level | L5 — Model prediction only; no actual studies linked |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a mechanism-to-indication bridge cannot be established at this time.

The combination contains pharmacologically active ingredients spanning multiple mechanisms: **Activated Charcoal** acts as a non-specific adsorbent; **Apomorphine HCl** is a dopamine D1/D2 receptor agonist with emetic and antiparkinsonian activity; **Ipecac** contains emetine and cephaeline; **Colchicum autumnale** provides colchicine, a tubulin polymerisation inhibitor used in gout. The remaining ingredients (Aethusa cynapium, Bryonia alba, Lycopodium clavatum, Strychnos ignatii, Strychnos nux-vomica, Sus scrofa esophagus/stomach, Watermelon) are typical of homeopathic formulations.

Because no single DrugBank ID could be assigned to this multi-component entry, the TxGNN knowledge-graph and deep-learning pipelines could not generate a disease-score ranking. A repurposing hypothesis will require either (1) splitting the combination into individual active ingredients for separate TxGNN queries, or (2) identifying the primary pharmacologically active component and running the pipeline on that ingredient alone.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a whole.

---

## Literature Evidence

Currently no related literature available for this combination as a whole.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note for reviewers:** Apomorphine HCl and Colchicine (from *Colchicum autumnale*) carry significant toxicity profiles. Apomorphine requires careful monitoring for cardiovascular and CNS effects; colchicine has a narrow therapeutic index and risk of bone marrow suppression. Any downstream evaluation must address these components individually before proceeding.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predicted indications because this multi-component string could not be mapped to a DrugBank ID, leaving both the prediction score and evidence linkage empty. A repurposing evaluation cannot be meaningfully conducted without a valid drug node in the knowledge graph.

**To proceed, the following is needed:**

- **Decompose the combination**: Re-run the TxGNN pipeline for each pharmacologically active ingredient separately (priority candidates: Apomorphine HCl → DrugBank DB00714; Colchicine from *Colchicum autumnale* → DrugBank DB01590; Emetine from Ipecac → DrugBank DB13245).
- **Identify the lead compound**: Determine which ingredient(s) are intended to carry the primary therapeutic effect before selecting a repurposing target disease.
- **Retrieve MOA data**: Query DrugBank API for each individual component to populate mechanism-of-action fields (currently DG002 — High severity gap).
- **Retrieve safety data**: Download and parse package insert PDF from the originating regulatory agency to populate warnings and contraindications (currently DG001 — Blocking severity gap).
- **Re-submit Evidence Pack**: Once a DrugBank ID is resolved for the lead compound, regenerate the Evidence Pack to obtain a TxGNN score and evidence linkage before advancing to S1 safety assessment.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

